Evidence map›Paper›PMID 40925342›Full record

Trial reportThe Journal of international medical research2025

Efficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy plus surgery in advanced ovarian cancer patients.

Chang Yanan, Liu Ting, Cao Wei Li, Xu Yaxin, Chen Hong

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Chang YananObstetrics and Gynecology Department, The Fifth Hospital of Wuhan, China.ORCID 0009-0007-1629-6546
Liu TingObstetrics and Gynecology Department, Wuhan Yangtze River Shipping General Hospital, China.
Cao Wei LiWomen's Health Department, Hubei Maternal and Child Health Hospital, China.
Xu YaxinObstetrics and Gynecology Department, Dongguan People's Hospital, China.
Chen HongObstetrics and Gynecology Department, Wuhan University Zhongnan Hospital, China.ORCID 0000-0002-8845-2575

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectiveThis study aimed to evaluate the efficacy and safety of hyperthermic intraperitoneal intraoperative chemotherapy (HIPEC) in patients with advanced ovarian cancer.MethodsA total of 200 patients with advanced ovarian cancer were enrolled in this retrospective study and randomly allocated to two groups (research registry number: 11353). On the first day after abdominal closure, routine treatment was performed in the non-HIPEC group, whereas HIPEC was performed in the HIPEC group. The surgical outcomes, overall survival, progression-free survival, side effects, and quality of life of patients were compared between the two groups, and the risk factors for overall survival and progression-free survival were analyzed.ResultsThe basic information of the patients showed no significant difference between the two groups (p > 0.05). There was no significant difference in the time from surgery to first flatus, postoperative hospital stay, abdominal pain, bleeding, leakage, or other blood indices between the two groups (p

Indexed as

Hyperthermic Intraperitoneal ChemotherapyOvarian NeoplasmsAdultAgedCombined Modality TherapyCytoreduction Surgical ProceduresFemaleHumansIntraoperative CareMiddle AgedProgression-Free SurvivalQuality of LifeRetrospective StudiesTreatment OutcomeAdvanced ovarian cancerhyperthermic intraperitoneal intraoperative chemotherapyoverall survivalprogression-free survivalrecurrence

Identifiers

PMID40925342
PMCPMC12421004

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.